Clinical Report: 2026 AACR Bladder Cancer Highlights

Overview

The 2026 AACR conference presented updates in bladder cancer treatment, including the efficacy of adjuvant nivolumab and the approval of durvalumab in combination with chemotherapy.

Background

Recent advancements in immunotherapy and combination therapies have shown promise in enhancing disease-free survival and overall survival rates in patients with muscle-invasive bladder cancer.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• Adjuvant nivolumab maintains disease-free survival benefits with a trend towards improved overall survival.
• Perioperative durvalumab combined with chemotherapy is associated with higher complete response rates in muscle-invasive bladder cancer.
• The 2026 EAU guidelines incorporate new recommendations for HER2 testing and the use of trastuzumab deruxtecan.
• Durvalumab received FDA approval for use in combination with cisplatin/gemcitabine for muscle-invasive bladder cancer.
• Atezolizumab was approved for adjuvant treatment in patients with molecular residual disease after cystectomy.

Clinical Implications

Clinicians should consider the latest guidelines and approvals when developing treatment plans for their patients.

Conclusion

The findings from the 2026 AACR conference highlight updates in bladder cancer treatment.

Related Resources & Content

1. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2026 -- 2026 AACR Bladder Cancer Highlights
2. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer - Uroweb, 2026 -- EAU Guidelines Update
3. FDA approves durvalumab for muscle invasive bladder cancer | FDA, 2025 -- FDA Approval of Durvalumab
4. FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer | FDA, 2026 -- FDA Approval of Atezolizumab
5. dana-farber — Bladder Cancer Conference Highlights from ASCO GU 2025
6. dana-farber — Bladder Cancer Highlights presented by Michael Serzan, MD
7. dana-farber — Bladder Cancer Highlights from ASCO 2025
8. dana-farber — 2026 AACR Renal Cell Carcinoma Highlights
9. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer - Uroweb
10. FDA approves durvalumab for muscle invasive bladder cancer | FDA
11. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | New England Journal of Medicine
12. FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease | FDA
13. FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer | FDA
14. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf
15. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial - ScienceDirect
16. EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). | Journal of Clinical Oncology
17. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial - PubMed
18. Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK. | Journal of Clinical Oncology
19. FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer | FDA
20. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | FDA
21. FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer | FDA